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	 Bis‐pyrazoline	 darivatives	 (2a‐e) built	 around	 the	 alkyl	 chains	 of	 varying	 length	 were
synthesized	 in	 good	 yield	 by	 refluxing	 bis‐chalcones	 (1a‐e)	 with	 phenyl	 hydrazine	 in
CH3COOH	and	ethanol.	The	structures	of	these	compounds	were	elucidated	by	IR,	1H	NMR,	13C
NMR,	Mass	(ESI)	spectrometries	and	their	purities	were	confirmed	by	elemental	analyses.	The
antibacterial	activity	of	 these	compounds	were	evaluated	by	 the	disc	diffusion	assay	against
two	 Gram‐positive	 and	 two	 Gram‐negative	 bacteria	 and	 then	 the	 minimum	 inhibitory
concentration	 of	 compounds	 were	 determined.	 The	 compounds	 1,4‐bis[1‐(2‐oxyphenyl)‐5‐
(furan‐2‐yl)‐4,5‐dihydro‐1H‐pyrazole]	 butane	 (2a)	 and	 1,10‐bis[1‐(2‐oxyphenyl)‐5‐(furan‐2‐
yl)‐4,5‐dihydro‐1H‐pyrazole]decane	 (2e)	 are	 better	 antibacterial	 agent	 as	 compared	 to
Tetracycline	and	Gentamicin.	
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1.	Introduction	
	
Drinking	 water	 involving	 of	 emerging	 pathogens	
Aeromonas	 hydrophila,	 Yersinia	 enterocolitica,	 Listeria	
monocytogenes	and	Staphylococcus	aureus	are	important	source	
of	 human	 gastrointestinal	 infections	 [1].	 It	 is	 speculated	 that	
resistance	 to	multiple	 antibiotics	 in	pathogens	 isolate	may	 be	
mediated	by	several	co‐inducible	enzymes	under	the	selection	
pressure	 of	 certain	 widely	 prescribed	 antibiotics.	 Due	 to	 the	
production	 of	 multiple	 inducible,	 the	 resistance	 to	 β‐lactam	
antibiotics	 chromosomally	 encoded	β‐lactames	 [2].	Resistance	
to	the	third	generation	cephalosporin	is	known	to	be	associated	
with	 the	 derepression	 of	 the	 chromosomal	 enzymes	 [3].	
Tetracycline	 resistance	 is	most	 commonly	mediated	 either	 by	
active	 efflux	 of	 tetracycline	 from	 the	 cell	 or	 by	 ribosomal	
protection,	and	in	rare	cases,	through	direct	inactivation	of	the	
antibiotic	or	by	mutations	in	the	16S	r‐RNA	that	prevent	biding	
tetracycline	 to	 the	 ribosome	 [4].	 The	 effective	 treatment	 for	
gastrointestinal	 is	metronidazole;	 however,	 lengthy	 treatment	
or	high	doses	often	cause	side	effects	such	as	headache,	nausea,	
vomiting,	dry	mouth,	metallic	taste,	dizziness,	and	neurological	
complications	 [5‐7].	 The	 chemistry	 of	 cyclised	 heterocyclic	
systems	especially	containing	pyrazole	moiety	has	been	largely	
investigated	due	to	their	effective	use	in	pharmacological	areas	
[8‐16].	Chalconoids	group	are	 the	 chalcone	compounds	which	
are	the	open	chain	molecule	having	two	aromatic	ring	liked	by	
the	 carbon	 fragment,	 exhibit	 a	 wide	 spectrum	 of	 beneficial	
biological	 activity	 anti‐inflammatory,	 anti‐invasive	 and	 optical	
properties	 [17].	 The	 development	 for	 the	 synthesis	 of	 five	
member	heterocyclic	 from	readily	available	reagents	 is	one	of	
the	 major	 challenges	 in	 organic	 synthesis.	 Among	 five	
membered	 heterocycles,	 pyrazoline	 and	 imidazole	 are	
represents	 great	 importance	 in	 biological	 activities	 like,	
antidepressant	 [18],	 anticonvulsant	 [19],	 antimicrobial	 [20],	
analgesics	 [21]	 and	 antitumor	 [22].	 In	 fact,	 pyrazoline	
derivative	 is	 now	 widely	 used	 in	 the	 market	 as	 anti‐
inflammatory	 [23],	 analgesics	 [24],	 antibacterial	 [25],	
antifungal	[26],	antituberculosis	[27],	anticonvolusant	[28]	and	
potential	anticytokine	agents	[29,30].	Recently,	some	attention	
has	 also	 been	 focused	 upon	 the	 reactions	 of	 hydroxyl	
substituted	 chalcones	 can	 be	 O‐alkylated	 under	 the	 basic	
medium	 with	 a	 suitable	 alkylating	 agent	 to	 give	 bifunctional	
bis‐chalcones	 molecules	 which	 are	 formed	 by	 liking	 two	
chalcone	 moieties	 together	 through	 the	 carbon	 chains	 of	
varying	 length	 and	 structures.	 By	 keeping	 this	 aspect	 in	 view	
the	present	researchers	are	 focused	upon	the	transformations	
of	bis‐chalcones	1a‐e	 to	bis‐pyrazolines	2a‐e	 built	 around	 the	
alkyl	 chains	 consisting	 of	 four	 to	 ten	 methylene	 groups	 and	
their	 increasing	 importance	 in	 pharmaceutical	 and	 biological	
field.	In	this	paper,	we	have	to	synthesize	some	novel	series	of	
bis‐pyrazoline	 derivative	 from	 alkoxy	 based	 bis‐chalcones	 as	
good	anti‐bacterial	agents.	
	
2.	Experimental	
	
All	 the	 chemicals	 were	 purchased	 from	 Aldrich	 Chemical	
Company	 (U.S.A)	 and	were	 used	without	 further	 purification.	
The	reactions	were	monitored	by	TLC	plates	were	coated	with	
silica	gel	suspended	in	MeOH‐CHCl3	and	iodine	vapors	used	as	
visualizing	agent.	Percolated	aluminum	silica	gel	60F	254	thin	
layer	 plates	 procured	 from	 Merck	 (Germany).	 All	 melting	
points	 were	 measured	 with	 a	 capillary	 apparatus	 and	 are	
uncorrected.	All	the	compounds	were	routinely	checked	by	IR,	
1H	NMR,	13C	NMR,	mass	spectrometry	and	elemental	analyses.	
IR	spectra	were	recorded	in	KBr	on	a	Perkin‐Elmer	model	1620	
FTIR	 spectrophotometer.	 1H	 NMR	 and	 13C	 NMR	 spectra	 were	
recorded	 at	 ambient	 temperature	 using	 a	 Bruker	 SpectroSpin	
DPX‐400	 MHz	 spectrophotometer	 in	 CDCl3	 and	 DMSO.	 The	
following	 abbreviations	 were	 used	 to	 indicate	 the	 peak	
multiplicity	 s‐	 singlet,	 d‐	 doublet,	 t‐	 triplet,	 m‐	multiplet.	 The	
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mass	spectra	have	been	scanned	on	the	Waters	Micromass	Q‐T	
of	 Micro	 (ESI)	 spectrometer.	 Anhydrous	 sodium	 sulfate	 was	
used	as	a	drying	agent	for	the	organic	phase.	
	
2.1.	Synthesis	of	chalcone		
	
2.1.1.	Synthesis	of	(E)‐3‐(furan‐2‐yl)‐1‐(2‐hydroxyphenyl)	
prop‐2‐en‐1‐one	(1)	
	
A	suspension	of	О‐hydroxy	acetophenone	(5	g,	0.0004	mol)	
and	furfural	aldehyde	(4.5	g,	0.0004	mol)	in	ethanolic	solution	
of	 NaOH	 (30%)	 was	 stirred	 for	 8	 hrs	 at	 room	 temperature.	
After	 the	 completion	 of	 reaction,	 the	 reaction	 mixture	 was	
poured	 into	 acidic	 ice	 water	 pH	 =	 2	 (adjusted	 by	 HCl)	 to	
produce	 a	 solid	 compound	 which	 was	 filtered	 under	 suction	
and	washed	with	H2O.	The	solid	was	filtered	recrystallized	from	
CH3OH:CDCl3	 (3:1)	 to	 obtain	 a	 pure	 pure	 chalcone,	 1,	 [31]	
(Scheme	1).	
(E)‐3‐(furan‐2‐yl)‐1‐(2‐hydroxyphenyl)prop‐2‐en‐1‐one	 (1):	
Yellow	needle.	Yield:	95%.	M.p.:	84	oC.	IR	(KBr,	υmax,	cm‐1):	1634	
(C=O),	2949	(O‐H).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	12.7	(1H,	
s,	‐OH),	8.02	(1H,	d,	Jtrans	=	15.4	Hz,	H‐3),	7.7	(1H,	t,	Jtrans	=	15.1	
Hz,	H‐2),	 7.34	 (1H,	 d{dd},	 Jpmo	 =	 1.6	Hz,	 3.5	Hz,	 8.1	Hz,	 Ar‐H),	
7.25	(1H,	m,	Ar‐H),	7.13	(1H,	m,	Ar‐H),	7.02	(1H,	dd,	Ar‐H	),	7.3	
(1H,	t,	Ar‐H	),	6.9	(1H,	m,	Ar‐H	),	6.7	(1H,	t,	Ar‐H	).	13C	NMR	(400	
MHz,	 CDCl3,	 δ,	 ppm):	 192.4	 (C=O),	 142.6	 (C=C),	 137.8	 (C=C),	
152.8,	 150.7,	 148.6,	 138.2,	 136.2,	 129.4,	 128.7,	 127.3,	 125.5,	
123.4	(Ar‐C).	GC‐MS	(m/z):	215	[M+].	Anal.	calcd.	 for	C13H10O3:	
C,	72.89;	H,	4.67.	Found:	C,	72.85;	H,	4.64%.	
	
2.1.2.	General	procedure	for	the	synthesis	of	bis‐chalcone	
(1a‐e)	
	
A	suspension	of	 furan	chalcone	(2.0	g,	0.008	mol),	1,	with	
suitable	 α‐ω‐di‐bromo	 alkane	 (1,4‐dibromobutane,	 1,5‐
dibromopentane,	 1,6‐dibrpmohexane,	 1,8‐dibromooctane	 and	
1,10‐dibromodecane)	 (0.0050	 mol),	 anhydrous	 K2CO3	 (1.0	 g)	
and	 phase	 transfer	 catalysts	 (PTC)	 (Tetra	 butyl	 ammonium	
iodide)	 (1.0	g)	 in	dry	acetone	was	 refluxed	with	 stirring	 for	8	
hrs.	 at	 room	 temperature.	 The	 progress	 of	 reaction	 was	
monitored	 by	 thin	 layer	 chromatography	 (TLC).	 After	 the	
completion	of	reaction,	the	reaction	mixture	was	turned	white	
was	 pour	 into	 acidic	 ice	water	 to	~pH	=	 2	 (adjusted	 by	HCl).	
The	 precipitated	 solid	 was	 filtered	 and	 recrystallized	 from	
CH3OH:CHCl3	(3:1)	to	obtain	pure	solids	(Scheme	1).		
(2E,2'E)‐1,1'‐((butane‐1,4‐diylbis(oxy))bis(2,1‐phenylene))	
bis(3‐(furan‐2‐yl)prop‐2‐en‐1‐one)	 (1a):	 Brown	 light.	 Yield:	
85%.	M.p.:	116	oC.	IR	(KBr,	υmax,	cm‐1):	3110	(Ar‐H),	1600	(C=O),	
1238,	 1021	 (C‐O),	 1548	 (C=C).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	
ppm):	7.64	(2H,	dd,	Ar‐H),	7.36	(2H	dd,	Jtrans	=	15.2	Hz,	H‐2),	7.4	
(4H,	t,	Ar‐H),	7.2	(2H,	dd,	Jtrans	=	15.4	Hz,	H‐3),	7.03	(2H,	d{dd},	
Jpmo	=	0.8	Hz,	1.04	Hz,	8.3	Hz,	Ar‐H),	6.8	(2H,	d,	Ar‐H),	6.6	(2H,	
dd,	Ar‐H),	6.4	(2H,	q,	Jp	=	1.8	Hz,	Ar‐H),	4.02	(4H,	t,	Jvis	=	6.2	Hz,	‐
CH2),	2.01(4H,	q,	J	=	5.9	Hz,	‐CH2).	13C	NMR	(400	MHz,	CDCl3,	δ,	
ppm):	 192.1	 (C=O),	 144.6	 (C=C),	 139.4	 (C=C),	 149.8,	 148.8,	
147.2,	 138.2,	 132.7,	 129.6,	 128.4,	 128.1,	 125.7,	 123.2	 (Ar‐C),	
78.2	(OCH2),	68.7	(CH2).	GC‐MS	(m/z):	483	[M+].	Anal.	calcd.	for	
C30H26O6:	C,	74.68;	H,	5.39;	Found:	C,	74.65;	H,	5.35%.	
(2E,2'E)‐1,1'‐((pentane‐1,5‐diylbis(oxy))bis(2,1‐phenylene))	
bis(3‐(furan‐2‐yl)prop‐2‐en‐1‐one)	 (1b):	 Brown	 light.	 Yield:	
85%.	M.p.:	122	oC.	IR	(KBr,	υmax,	cm‐1):	3110	(Ar‐H),	1610	(C=O),	
1652	(C=C),	1548	(CH	=	CH).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
8.02	(2H,	d,	Ar‐H),	7.67	(2H,	d,	Jtrans	=	15.8	Hz,	H‐2),	7.58	(4H,	d,	
Ar‐H),	7.25	(2H,	d,	Ar‐H),	7.05	(2H,	d{dd},	Jpmo	=	0.8	Hz,	1.0	Hz,	
7.6	Hz,	Ar‐H),	7.42	(2H,	d,	Jtrans	=	15.8	Hz,	H‐3),	6.92	(4H,	d,	Ar‐
H),	4.04	(4H,	 t,	 Jvic	=	6.3	Hz,	OCH2),	1.86	(4H,	quintet,	 Jvic	=	6.3	
Hz,	 ‐CH2),	1.67	 (2H,	quintet,	 Jvic	 =	6.3	Hz,	 ‐CH2).	 13C	NMR	(400	
MHz,	 CDCl3,	 δ,	 ppm):	 191.8	 (C=O),	 145.7	 (C=C),	 138.5	 (C=C),	
148.7,	 147.6,	 147.5,	 136.3,	 133.5,	 129.8,	 128.7,	 127.2,	 125.4,	
123.7	 (Ar‐C),	 77.2	 (OCH2),	 68.5	 (CH2),	 47.09	 (CH2).	 GC‐MS	
(m/z):	 497	 [M+].	 Anal.	 calcd.	 for	 C31H28O6:	 C,	 75.00;	 H,	 5.64;	
Found:	C,	74.96;	H,	5.60%.	
	
	
	
Scheme	1	
		
(2E,2'E)‐1,1'‐((hexane‐1,6‐diylbis(oxy))bis(2,1‐phenylene))	
bis(3‐(furan‐2‐yl)prop‐2‐en‐1‐one)	 (1c):	 Dark	 Brown.	 Yield:	
75%.	M.p.:	108	oC.	IR	(KBr,	υmax,	cm‐1):	3105	(Ar‐H),	1602	(C=O),	
1545	(C=C),	1257,	1210,	1006	(C‐O).	1H	NMR	(400	MHz,	CDCl3,	
δ,	ppm):	7.82	(2H,	dd.	 Jtrans	=	15.2	Hz,	H‐2),	6.83	(2H,	d,	Ar‐H),	
7.52	(2H,	m,	Ar‐H),	7.45	(2H,	d{dd},	 J	=	1.5	Hz,	1.8	Hz,	8.2	Hz,	
Ar‐H),	7.26	(2H,	m,	Ar‐H),	7.04	(2H,	m,	Ar‐H),	7.02	(4H,	m,	Ar‐
H),	6.95	(2H,	dd,	Jtrans	=	15.2	Hz,	H‐3),	4.05	(4H,	t,	Jvis	=	6.5	Hz,	‐
CH2),	 2.06	 (4H,	 q,	 Jvis	 =	 6.2	Hz,	 ‐CH2),	 2.02	 (2H,	 q,	 ‐CH2),	 1.82	
(2H,	m,	‐CH2).	13C	NMR	(400	MHz,	CDCl3,	δ,	ppm):	192.2	(C=O),	
145.5	 (C=C),	 140.2	 (C=C),	 148.8,	 147.2,	 137.8,	 136.5,	 133.7,	
132.8,	 129.1,	 128.2,	 125.5,	 124.2	 (Ar‐C),	 77.8	 (‐OCH2),	 68.6	 (‐
CH2),	56.24	(‐CH2),	48.08	(‐CH2).	GC‐MS	(m/z):	511	[M+].	Anal.	
calcd.	for	C32H30O6:	C,	55.29;	H,	5.88;	Found:	C,	55.26;	H,	5.84%.	
(2E,2'E)‐1,1'‐((octane‐1,8‐diylbis(oxy))bis(2,1‐phenylene))	
bis(3‐(furan‐2‐yl)prop‐2‐en‐1‐one)	 (1d):	 Light	 brown.	 Yield:	
75%.	M.p.:	102	oC.	IR	(KBr,	υmax,	cm‐1):	3107	(Ar‐H),	1607	(C=O),	
1547	 (C=C),	 1210,	 1006	 (C‐O).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	
ppm):	 7.65	 (2H,	 dd,	 Jtrans	 =	 15.2	 Hz,	 H‐2),	 7.45	 (4H,	m,	 Ar‐H),	
7.40	(2H,	dd.	Jtrans	=	15.2	Hz,	H‐3),	7.3	(2H,	d,	Ar‐H),	7.02	(2H,	dt,	
Ar‐H),	6.45	(2H,	d{dd},	Jpmo	=	1.8	Hz,	3.8	Hz,	6.8	Hz,	Ar‐H),	6.97	
(2H,	dd,	Ar‐H),	6.63	(2H,	d,	Ar‐H),	4.06	(4H,	t,	Jvic	=	6.2	Hz,	‐CH2),	
1.74	(4H,	q,	Jvic	=	5.8	Hz,	‐CH2),	1.5	(4H,	q,	Jvic	=	6.9	Hz,	‐CH2),	1.3	
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(4H,	q,	‐CH2).	13C	NMR	(400	MHz,	CDCl3,	δ,	ppm):	192.4	(C=O),	
144.6	 (C=C),	 139.4	 (C=C)	 148.4,	 147.4,	 138.6,	 135.4,	 132.7,	
129.6,	 128.4,	 128.1,	 125.7,	 123.2	 (Ar‐C),	 76.2	 (‐OCH2),	 67.6	 (‐
CH2),	58.26	(‐CH2),	48.03	(‐CH2).	GC‐MS	(m/z):	539	[M+].	Anal.	
calcd.	for	C34H34O6:	C,	75.83;	H,	6.31;	Found:	C,	75.80;	H,	6.28%.	
(2E,2'E)‐1,1'‐((decane‐1,10‐diylbis(oxy))bis(2,1‐phenylene))	
bis(3‐(furan‐2‐yl)prop‐2‐en‐1‐one)	 (1e):	 Light	 Brown.	 Yield:	
78%.	M.p.:	120	oC.	IR	(KBr,	υmax,	cm‐1):	3112	(Ar‐H),	1655(C=O),	
1552	 (C=C),	 1235,	 1017	 (C‐O).	 1H	 NMR	 (400	 MHz,	 CDCl3,	 δ,	
ppm):	7.66	(2H,	dd,	Jtrans	=	7.3	Hz,	H‐3),	7.42	(4H,	m,	Ar‐H),	7.39	
(2H,	dd.	Jtrans	=	15.2	Hz,	H‐2),	7.03	(2H,	dd,	J	=	0.8	Hz,	3.0	Hz,	8.2	
Hz,	Ar‐H),	6.9	(2H,	d,	Ar‐H),	6.73	(2H,	t,	Ar‐H),	6.63	(2H,	d,	Ar‐
H),	6.42	(2H,	d,	Ar‐H),	4.05	(4H,	t,	J	=	6.2	Hz,	‐CH2),	1.80	(4H,	q,	J	
=	6.4	Hz,	‐CH2),	1.74	(4H,	q,	‐CH2),	1.60	(4H,	m,	‐CH2),	1.41	(4H,	
m,	‐CH2).	13C	NMR	(400	MHz,	CDCl3,	δ,	ppm):	191.7	(C=O),	145.6	
(C=C),	 138.9	 (C=C)	 149.3,	 148.2,	 137.8,	 136.4,	 133.9,	 129.7,	
128.9,	 127.6,	 124.8,	 123.5	 (Ar‐C),	 76.2	 (‐OCH2),	 67.6	 (‐CH2),	
52.46	 (‐CH2),	 58.26	 (‐CH2),	 48.03	 (‐CH2).	 GC‐MS	 (m/z):	 567	
[M+].	Anal.	calcd.	for	C36H38O6	:	C,	76.32;	H,	6.71;	Found:	C,	76.29;	
H,	6.68%.	
	
2.1.3.	General	procedure	for	the	synthesis	of	bis‐pyrazolines	
(2a‐e)	
	
Bis‐pyrazoline,	2a‐e,	was	obtained	from	the	reaction	of	1a‐
e	(0.00087	mol),	phenyl	hydrazine	(0.75	mL,	0.00175	mol)	and	
glacial	acetic	acid	(5	mL)	 in	dry	ethanol	(25	mL)	was	refluxed	
for	 12	 hrs.	 The	 progress	 of	 reaction	 was	 monitored	 by	 TLC.	
After	completion	the	reaction,	the	reaction	mixture	was	cooled	
in	refrigerator,	 to	obtain	precipitated	solid	was	filtered	and	 in	
crystallized	 from	 CH3OH	 to	 yield	 bis‐pyrazolines	 2a‐e	 [32]	
(Scheme	1).		
(S)‐3‐(2‐(4‐(2‐((R)‐1‐carbamothioyl‐5‐(furan‐2‐yl)‐4,5‐
dihydro‐1H‐pyrazol‐3‐yl)phenoxy)butoxy)phenyl)‐5‐(furan‐2‐yl)‐
4,5‐dihydro‐1H‐pyrazole‐1‐carbothioamide	 (2a):	 Brown	 light.	
Yield:	87%.	M.p.:	182	oC.	IR	(KBr,	υmax,	cm‐1):	3051	(Ar‐H),	1482	
(N‐N),	 1596	 (C	 =	N).	 1H	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 7.45	
(2H,	t,	Ar‐H),	7.28	(10H,	m,	Ar‐H),	7.18	(4H,	m,	Ar‐H),	7.46	(2H,	
d{dd},	Jp,	m,	o	=	1.7	Hz,	3.2	Hz,	8.1	Hz,,	Ar‐H),	6.98	(4H,	dd,	Ar‐H),	
6.86	 (2H,	 d,	Ar‐H),	5.23	 (2Hx,	dd,	 Jxa	 =	 6.0	Hz,	 Jxb	=	11.6	HZ	 ),	
3.78	(2Ha,	dd,	Jab	=	16.7	Hz,	Jax	=	6.0	Hz	),	3.52	(2Hb,	dd,	Jba	=	16.7	
Hz,	Jbx	=	11.6	Hz	),	4.05	(4H,	t,	Jvic	=	6.8	Hz,	‐CH2	),	2.01	(	4H,	q,	‐
CH2).	 13C	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 156.8	 (C=N),	 148.8,	
147.2,	 146.2,	 144.1,	 142.8,	 130.1,	 129.1,	 126.8,	 124.6,	 124.8,	
121.9,	120.5,	119.2,	113.7,	112.9	 (Ar‐C),	77.3	 (pyra.	 ring	C‐4	 ),	
67.7	(‐OCH2	),	60.4	(CH2	),	47.09	(pyra.	ring,	C‐5	).	GC‐MS	(m/z):	
663	[M+].	Anal.	calcd.	for	C42H38O4N4:	C,	76.13,	H,	5.74,	N,	8.45;	
Found:	C,	76.09,	H,	5.70,	N,	8.41%.	
(S)‐3‐(2‐((5‐(2‐((R)‐1‐carbamothioyl‐5‐(furan‐2‐yl)‐4,5‐
dihydro‐1H‐pyrazol‐3‐yl)phenoxy)pentyl)oxy)phenyl)‐5‐(furan‐
2‐yl)‐4,5‐dihydro‐1H‐pyrazole‐1‐carbothioamide	 (2b):	 Brown	
light.	Yield:	88%.	M.p.:	175	oC.	IR	(KBr,	υmax,	cm‐1):	3051	(Ar‐H),	
1514	 (N‐N),	 1586	 (C=N).	 1H	 NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	
7.72	 (4H,	 d,	 Ar‐H),	 7.37	 (2H,	 dd,	 Jp.o	 =	 1.1,	 7.8	Hz,	 Ar‐H),	 7.30	
(6H,	m,	Ar‐H),	7.20	(4H,	m,	Ar‐H),	7.11	(4H,	m,	Ar‐H),	6.85	(4H,	
dd,	Ar‐H),	5.22	(2HX,	dd,	Jxa	=	7.1	Hz,	Jxb	=	11.7	Hz,	),	3.95	(4H,	t,	
Jvic	=	6.3	Hz,	‐OCH2),	3.80	(2Hb,	dd,	Jbx	=	11.7	Hz,	Jba	=	16.2	Hz),	
3.11	(2Ha,	dd,	Jax	=	7.1	Hz,	 Jab	=	16.2	Hz),	1.82	(4H,	q,	Jvic	=	6.3	
Hz,	 ‐CH2),	1.64	 (2H,	q,	 Jvic	=	6.3	Hz,	 ‐CH2).	 13C	NMR	(400	MHz,	
CDCl3,	δ,	ppm):	155.7	(C=N),	148.7,	147.6,	146.5,	145.3,	143.7,	
130.2,	 129.4,	 125.7,	 124.5,	 124.9,	 122.7,	 121.7,	 118.4,	 114.8,	
113.7	(Ar‐C),	78.51	(‐OCH2),	67.48	(pyra.	ring	C‐4),	66.87	(CH2),	
61.6	(CH2),	48.08	(pyra.	ring,	C‐5).	GC‐MS	(m/z):	677	[M+].	Anal.	
calcd.	for	C43H40O4N4:	C,	76.33,	H,	5.91,	N,	8.28;	Found:	C,	76.30,	
H,	5.88,	N,	8.24%.	
(S)‐3‐(2‐((6‐(2‐((R)‐1‐carbamothioyl‐5‐(furan‐2‐yl)‐4,5‐
dihydro‐1H‐pyrazol‐3‐yl)phenoxy)hexyl)oxy)phenyl)‐5‐(furan‐2‐
yl)‐4,5‐dihydro‐1H‐pyrazole‐1‐carbothioamide	 (2c):	 Dark	
brown.	Yield:	85%.	M.p.:	167	oC.	IR	(KBr,	υmax,	cm‐1):	3030	(Ar‐
H),	1485	(N‐N),	1590	(C=N).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
7.30	(8H,	m,	Ar‐H),	7.45	(2H,	d{dd},	Jpmo	=	1.2	Hz,	2.3	Hz,	8.3	Hz,	
Ar‐H),	7.23	(4H,	m,	Ar‐H),	7.14	(4H,	m,	Ar‐H),	6.91	(2H,	t,	Ar‐H),	
6.8	(2H,	t,	Ar‐H),	5.26	(2HX,	dd,	Jxa	=	6.4	Hz,	JXb	=	11.7	Hz),	3.79	
(2Ha	dd,	Jax	=	6.4	Hz,	Jab	=	16.4	Hz),	3.53	(2Hb,	dd,	Jba	=	16.4	Hz,	
Jbx	=	11.7	Hz),	4.01(4H,	t,	Jvic	=	5.8	Hz,	‐CH2	),	3.92	(4H,	q,	Jvic	=	
6.2	 Hz,	 ‐CH2),	 2.1	 (4H,	 q,	 ‐CH2).	 13C	 NMR	 (400	MHz,	 CDCl3,	 δ,	
ppm):	 156.9	 (C=N),	 147.9,	 147.2,	 145.6,	 144.7,	 143.9,	 131.4,	
128.7,	125.6,	124.8,	123.6,	122.8,	121.9,	120.4,	114.5,	113.8	(Ar‐
C),	 76.13	 (pyra.	 ring,	 C‐4),	 68.09	 (‐OCH2),	 62.56	 (	 CH2	 ),	 61.8	
(CH2	 ),	 47.02	 (pyra.	 ring,	 C‐5).	 GC‐MS	 (m/z):	 691	 [M+].	 Anal.	
calcd.	for	C44H42O4N4:	C,	76.52;	H,	6.08;	N,	8.11;	Found:	C,	76.48,	
H,	6.04,	N,	8.08%.		
(S)‐3‐(2‐((8‐(2‐((R)‐1‐carbamothioyl‐5‐(furan‐2‐yl)‐4,5‐
dihydro‐1H‐pyrazol‐3‐yl)phenoxy)octyl)oxy)phenyl)‐5‐(furan‐2‐
yl)‐4,5‐dihydro‐1H‐pyrazole‐1‐carbothioamide	 (2d):	 Light	
brown.	Yield:	88%.	M.p.:	176	oC.	IR	(KBr,	υmax,	cm‐1):	3030	(Ar‐
H),	1525	(N‐N),	1602	(C=N).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
7.62	(2H,	dd,	Jo.p.	=	1.0	Hz,	8.7	Hz,	Ar‐H),	7.32	(4H,	m,	Ar‐H),	7.20	
(2H,	m,	Ar‐H),	7.10	(6H,	m,	Ar‐H),	7.02	(4H,	dt,	J	=	1.0	Hz,	8.4	Hz,	
Ar‐H),	6.76	(4H,	dt,	Jp.o	=	1.0	Hz,	8.4	Hz,	Ar‐H),	6.68	(2H,	td,	J	=	
2.6	Hz,	4.8	Hz,	Ar‐H),	5.12	(2Hx,	dd,	Jxa	=	7.2	Hz,	JXb	=	12.2	Hz),	
3.81	(4H,	t,	Jvic	=	6.4	Hz,	‐	OCH2),	3.70	(2Hb,	dd,	Jbx	=	12.3	Hz,	Jba	
=	16.8	Hz	),	3.02	(2Ha,	dd,	Jax	=	7.2	Hz,	Jab	=	16.8	Hz	),	1.66	(4H,	
q,	Jvic	=	6.0	Hz,	‐CH2),	1.35	(4H,	m,	‐CH2),	1.28	(4H,	m,	‐CH2).	13C	
NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	 157.3	 (C	 =	 N),	 148.5,	 146.8,	
146.4,	 145.6,	 144.7,	 133.6,	 127.9,	 126.8,	 125.9,	 124.3,	 123.9,	
122.5,	121.6,	115.3,	114.6	 (Ar‐C),	 78.23(pyra.	 ring,	 C‐4),	77.24	
(OCH2	 ),	 67.54	 (CH2),	 63.87	 (CH2),	 62.32	 (CH2),	 48.43	 (pyra.	
ring,	C‐5).	GC‐MS	(m/z):	719[M+].	Anal.	calcd.	for	C46H46O4N4:	C,	
76.88;	H,	6.40;	N,	7.79;	Found:	C,	76.84;	H,	6.36;	N,	7.75%.		
(S)‐3‐(2‐((10‐(2‐((R)‐1‐carbamothioyl‐5‐(furan‐2‐yl)‐4,5‐
dihydro‐1H‐pyrazol‐3‐yl)phenoxy)decyl)oxy)phenyl)‐5‐(furan‐2‐
yl)‐4,5‐dihydro‐1H‐pyrazole‐1‐carbothioamide	 (2e):	 Light	
brown.	Yield:	85%.	M.p.:	184	oC.	IR	(KBr,	υmax,	cm‐1):	3034	(Ar‐
H),	1493	(N‐N),	1598	(C=N).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
7.33	(4H,	m,	Ar‐H	),	7.19	(	2H,	d,	Ar‐H),	7.15	(10H,	m	Ar‐H),	7.08	
(2H,	d{dd},	Jp,	m,	o	=	1.0	Hz,	2.2	Hz,	8.	Hz,	Ar‐H),	6.99	(4H,	m,	Ar‐H	
),	6.72	(2H,	m,	Ar‐H),	6.28	(2H,	m,	Ar‐H),	5.94	(2Hx,	dd,	Jxa	=	6.5	
Hz,	Jxb	=	11.0	Hz),	3.54	(2Ha,	dd,	Jab	=	16.1	Hz,	Jax	=	6.5	Hz),	3.32	
(2Hb,	dd,	Jba	=	16.1	Hz,	Jbx	=	11.0	Hz),	4.72	(4H,	t,	Jvic	=	5.3	Hz,	‐
CH2),	4.62	(6H,	q,	Jvic	=	5.8	Hz,	‐CH2),	2.52	(10H,	q,	Jvic	=	6.4	Hz,	‐
CH2).	 13C	NMR	 (400	MHz,	 CDCl3,	 δ,	 ppm):	 157.0	 (C=N),	 147.5,	
146.8,	 145.3,	 144.5,	 143.8,	 132.9,	 129.4,	 125.2,	 124.4,	 123.9,	
122.1,	121.5,	119.6,	115.3,	114.2	(Ar‐C),	77.43	(pyra.	ring,	C‐4),	
67.56	 (‐OCH2),	 65.78	 (CH2),	 64.12,	 (CH2),	 62.32	 (CH2),	 46.76	
(pyra.	 ring,	 C‐5).	 GC‐MS	 (m/z):	 747	 [M+].	 Anal.	 calcd.	 for	
C48H50O4N4:	C,	77.21;	H,	6.70;	N,	7.50;	Found:	C,	77.18;	H,	6.66;	
N,	7.46%.		
	
2.2.	In‐vitro	antibacterial	activities	
	
In	 vitro	 antibacterial	 activities	 of	 bis‐pyrazoline	 2a‐e	
derivatives	 were	 carried	 out	 using	 the	 culture	 of	 Aeromonas	
hydrophila	 (MTCC	 646),	 Yersinia	 enterocolitica	 (MTCC	 3099),	
Listeria	monocytogenes	(MTCC	657),	and	Staphylococcus	aureus	
(MTCC	 96)	 by	 the	 disc	 diffusion	 method.	 Gentamicin	 and	
Tetracycline	were	used	as	 the	standard	drugs,	whereas	DMSO	
poured	disk	was	used	as	negative	control.	DMSO	did	not	show	
inhibition	 against	 the	 tested	 organisms.	 Pure	 cultures	 were	
grown	 in	 brain	 heart	 infusion	 broth	 for	 sensitivity	 testing.	
Mueller	Hinton	agar	 (HiMedia)	 and	bis‐pyrazoline	compounds	
2a‐e	 absolutely	 diluted	 (concentration	 of	 40,	 30,	 20	 and	 10	
µg/mL)	were	applied	as	described	by	Bauer	et	al.	1966	[33].	A.	
hydrophila,	 Y.	 enterocolitica,	 L.	monocytogenes,	 and	 S.	 aureus	
strain	were	tested	against	 the	following	antibiotics	 (HiMedia):	
Tetracycline	30	µg	and	Gentamicin	10	µg.	After	enrichment	 in	
brain	 heart	 infusion	 broth	 for	 6‐8	 hrs	 at	 37	 oC,	 the	 cultures	
were	 streaked	 on	 Mueller	 Hinton	 agar	 plates	 using	 a	 cotton	
swab.	The	antibiotic	discs	and	prepared	compound	discs	were	
placed	on	the	agar	surface.		
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Table	1.	Antibacterial	activity	of	bis‐pyrazoline	derivatives,	positive	control	(Tetracycline	and	Gentamicin)	and	negative	control	(DMSO)	measured	by	the	Halo	
Zone	Test	(Unit,	mm).		
Compounds	
Minimum	Inhibitory	Concentration,	mm
A.	hydrophila	 Y.	enterocolitica	 L.	monocytogenes	 S.	aureus	
2a	 24.5	±	0.4	 22.4	±	0.5 21.3	±	0.2 25.8	±	0.4
2b	 14.5	±	0.5	 15.5	±	0.2 18.4	±	0.4 14.6	±	0.3
2c	 19.5	±	0.2	 18.5	±	0.5	 16.5	±	0.3	 15.5	±	0.2	
2d	 15.2	±	0.4	 17.6	±	0.4	 15.8	±	0.2	 14.6	±	0.3	
2e	 25.2	±	0.6	 23.6	±	0.3 24.2	±	0.4 22.7	±	0.2
Tetracycline	 13	 20	 12	 14	
Gentamicin	 11	 16	 15	 14	
DMSO	 ‐	 ‐ ‐ ‐	
	
	
After	 30	 min	 of	 pre‐diffusion	 time,	 the	 plates	 were	
incubated	at	37	oC	for	18‐24	h,	after	incubation,	the	diameter	of	
the	 inhibition	 zones	 were	 measured	 and	 compared	 to	 the	
interpretive	 chart	 of	 performance	 standards	 for	 antimicrobial	
disk	 susceptibility	 tests	 (HiMedia)	 and	 classified	 as	 resistant,	
intermediate	 or	 sensitive.	 The	 results	 of	 antibacterial	 activity	
and	Minimum	Inhibitory	Concentration	(MIC)	are	summarized	
in	Table	1.	
	
3.	Results	and	discussion	
	
The	 novel	 bis‐pyrazolines	 (2a‐e)	 were	 prepared	 in	 three	
steps,	starting	from	the	Claisen‐Schmidt	reaction	of	O‐hydroxy	
acetophenone	 with	 furfuraldehyde	 in	 the	 presence	 of	 NaOH	
(50%)	to	give	95%	yield	(1).	The	starting	bis	chalcones	(1a‐e)	
were	 obtained	 in	 good	 yields	 from	 the	 O‐alkylation	 of	 furan‐
chalcones	 with	 suitable	 α‐ω‐di‐bromo	 alkane	 (1,4‐
dibromobutane,	1,5‐dibromopentane,	1,6‐dibrpmohexane,	1,8‐
dibromooctane	 and	 1,10‐dibromodecane,	 respectively)	 in	 the	
presence	 of	 K2CO3/PTC/dry	 acetone	 (Scheme	 1).	 The	
cyclization	 of	 latter	 with	 phenyl	 hydrazine	 under	 alcoholic	
conditions	 led	 to	 the	 formation	 of	 new	 compounds	 (2a‐e)	
which	were	crystallized	from	CH3OH	to	give	pure	compounds	in	
moderate	yields.	All	the	compounds	are	insoluble	in	water	but	
soluble	 in	 organic	 solvents.	 The	 chemical	 structure	 of	 these	
compounds	 (1,	 1a‐e	 and	 2a‐e)	 were	 established	 by	 rigorous	
analysis	 of	 their	 elemental	 analysis	 IR,	 1H	NMR,	 13C	NMR	 and	
Mass	spectral	data.	
IR	spectra	of	starting	material	bis‐chalcone,	1a‐e,	displayed	
intense	absorptions	at	1600‐1655	cm‐1	and	1552‐1652	cm‐1	due	
to	 C=O	 and	 C=C	 stretching,	 respectively.	 IR	 bands	 provide	
significant	 indications	 for	 the	 formation	 of	 the	 cyclized	 bis‐
pyrazoline	 analogues	 of	 the	 bis‐pyrazoline,	 2a‐e.	 In	 addition,	
the	 IR	 spectra	 of	 the	 compounds	 showed	 νC=N	 stretching	 at	
1590‐1602	 cm‐1	 and	 ν(N‐N)	 stretching	 vibration	 at	 1482‐1525	
cm‐1,	 which	 also	 confirm	 the	 formation	 of	 desired	 bis‐
pyrazoline	compounds.	
In	the	1H	NMR	spectra,	the	downfield	resonance	of	the	H‐3	
as	compared	to	H‐2	could	be	ascribed	to	the	electron	deficient	
nature	of	the	β‐carbon	in	the	enone	moiety.	The	major	feature	
of	 the	 compounds	 2a‐e,	 Hx	 and	 Ha	 &	 Hb	 proton	 of	 bis‐
pyrazoline	ring	were	observed	as	doublet	of	doublet	at	δ,	5.12‐
5.94	ppm	(1H,	dd,	Jxa	=	6.0‐7.2	Hz,	JXb	=	11.0‐12.2	HZ)	and	3.32‐
3.95	 ppm	 (2H,	 dd,	 Jax	 =	 6.0‐7.2	 Hz,	 Jab	 =	 16.1‐16.8	 Hz),	
respectively,	 which	 clearly	 describes	 the	 inter‐relationship	
between	 the	Hx,	 Hb	 and	Ha.	 The	 strong	 deshielding	 of	 the	 C5	
(Ha	and	Hb)	protons	compared	with	the	C4	(Hx)	protons	of	the	
bis‐pyrazoline	 ring	 can	 be	 assumed	 due	 to	 its	 structure	
(Scheme	1).	The	protons	belonging	to	the	aromatic	ring	and	the	
other	cyclic	groups	were	observed	with	the	expected	chemical	
shift	and	integral	values.	
13C	NMR	spectra	of	the	compounds	2a‐e	were	recorded	in	
DMSO	 and	 spectral	 signals	 are	 in	 good	 agreement	 with	 the	
probable	 structures.	 The	 C4	 and	 C5	 carbon	 of	 bis‐pyrazoline	
resonated	 at	 67.48‐78.23	 and	 46.76‐48.08	 ppm,	 respectively.	
The	 carbon	 of	 C=O	 and	 C=C	 displayed	 signal	 at	 189.7‐193.2	
ppm	 and	 137.8‐145.7	 ppm	 in	 the	 all	 compounds.	 The	
compounds,	 2a‐e,	 showed	 two	 signal	 at	 155.7‐157.6	 ppm	
assigned	 to	C=N.	The	signals	due	 to	 the	aromatic	carbons	and	
the	 carbon	 at	 1‐N	 substituted	 aliphatic	 group.	 The	 other	
resonates	 were	 showed	 at	 their	 usual	 position	 in	 the	
experimental	 section.	 Encouraged	 by	 these	 cyclization	
reactions,	 it	was	 considered	 to	be	 of	major	 interest	 to	 extend	
this	study	on	the	bis‐chalcones,	1a‐e,	in	order	to	investigate	the	
effect	of	lengthy	methylene	chains	upon	the	formation	and	the	
stereo	chemical	features	of	the	bis‐pyrazoline	rings.	The	carbon	
atoms	 (C‐4	 and	 5)	 belonging	 to	 bis‐pyrazoline	 ring	 resulted	
resonances	 at	 δ,	 67.48	 and	 46.78	 ppm,	 respectively.	 The	
downfield	 resonance	 of	 former	 as	 compared	 to	 C‐4	 could	 be	
attributed	to	 its	benzylic	nature	and	proximity	to	the	nitrogen	
atom.	The	carbon	atoms	due	to	phenyl	rings	present	at	the	N‐1,	
C‐3	 and	 5,	 were	 observed	 at	 the	 expected	 positions	 in	 the	
aromatic	region.	
Characteristic	 peak	were	 observed	 in	 the	mass	 spectra	 of	
compounds	 molecular	 ion	 peak	 (M+.)	 were	 observed.	 The	
characteristics	peaks	observed	within	 the	mass	 spectra	of	bis‐
pyrazoline	compounds	are	given	in	experimental	section.	
All	 the	synthesized	compounds	2a‐e	were	evaluated	for	 in	
vitro	 antibacterial	 activity	 by	 using	 disc‐diffusion	method	 and	
the	diameter	of	zone	of	inhibition	was	measured	in	mm.	It	was	
found	 that	 all	 the	 compounds	2a‐e	were	 screened	 in	vitro	 for	
their	 antibacterial	 activity	 against	 a	 variety	 of	 Gram‐positive	
and	 Gram‐negative	 bacterial	 strains,	 like	 A.	 hydrophila,	 L.	
monocytogenes,	Y.	enterocolitica	and	S.	aureus.	Gentamicin	 (10	
mg)	and	Tetracycline	(30	mg)	were	taken	as	the	standard	drugs	
and	 DMSO	 was	 used	 as	 a	 blank.	 The	 in	 vitro	 studies	 result	
showed	 that	 the	 compounds	2a	 (10	mg)	 and	2e	 (30	mg)	 are	
highest	 activity	 against	 A.	 hydrophila,	 Y.	 enterocolitica,	 L.	
monocytogenes,	and	S.	aureses	among	all	the	pyrazolines	when	
compared	to	antibiotics.	The	susceptibility	of	the	bacteria	to	the	
test	 compounds	 were	 determined	 by	 the	 formation	 of	 an	
inhibitory	zone	after	48	h	of	incubation	at	37	oC.	The	molecular	
structure	of	these	active	compounds	showed	enhanced	activity.	
The	 distinct	 differences	 in	 the	 antibacterial	 property	 of	 these	
compounds	 further	 justify	 the	 purpose	 of	 this	 study.	 The	
importance	 of	 such	 work	 lies	 in	 the	 possibility	 that	 the	 new	
compounds	 might	 be	 more	 efficacious	 drugs	 against	 bacteria	
for	 which	 a	 thorough	 investigation	 regarding	 the	 structure‐
activity	 relationship,	 toxicity	 and	 in	 their	 biological	 effects	
which	 could	be	helpful	 in	designing	more	potent	 antibacterial	
agents	for	therapeutic	use.	On	the	basis	of	above	observations,	
modification	will	be	done	to	improve	antibacterial	activity.	
	
4.	Conclusions	
	
It	 may	 be	 concluded	 that	 this	 research	 involves	 the	
synthesis	 of	bis‐pyrazoline	 derivatives	 (2a‐e)	 of	bis‐chalcones	
(1a‐e).	Compounds	2a	and	2e	showed	highest	activity	against	
A.	hydrophila,	Y.	enterocolitica,	L.	monocytogenes,	S.	aureses	and	
better	antibacterial	agents	than	the	respective	standard	drugs.	
Thus	 the	 accumulation	 of	 the	 bis‐pyrazoline	 derivatives	 will	
better	 antibacterial	 agents	 as	 compared	 to	 Gentamicin	 and	
Tetracycline.	 The	 molecular	 structure	 of	 these	 active	
compounds	 showed	 property	 of	 the	 pyrazoline.	 These	
compounds	 might	 be	 more	 efficacious	 drugs	 against	 these	
Rani	and	Yusuf	/	European	Journal	of	Chemistry	3	(1)	(2012)	21‐25	 25	
 
bacteria	 and	 their	 biological	 effects	which	 could	 be	 helpful	 in	
designing	more	potent	antibacterial	agents	for	therapeutic	use.	
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